Colombia vs Guinea: Average cost of drugs for extensively drug-resistant tuberculosis
Colombia
5,370 constant 2022 US$
in 2024
Guinea
5,356 constant 2022 US$
in 2024
Colombia rank
8th
Guinea rank
9th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Colombia
- Guinea
How they compare
Colombia currently reports 5,370 constant 2022 US$ against 5,356 constant 2022 US$ in Guinea, a difference of 14 constant 2022 US$.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Guinea ahead.
Colombia ranks 8th and Guinea ranks 9th of 56 countries.
Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Colombia | Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,800 constant 2022 US$ | 8,964 constant 2022 US$ | 6,164 constant 2022 US$ | Guinea |
| 2020s | 1,658 constant 2022 US$ | 8,060 constant 2022 US$ | 6,402 constant 2022 US$ | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Colombia or Guinea?
- Colombia, at 5,370 constant 2022 US$ against 5,356 constant 2022 US$ in Guinea as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Colombia and Guinea?
- 14 constant 2022 US$, with Colombia ahead.
- How many years of comparable data are there for Colombia and Guinea?
- 6 years are reported by both, from 2019 to 2024.
- How do Colombia and Guinea rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Colombia ranks 8th and Guinea ranks 9th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.